Cullinan Therapeutics, INC Form 4 insider transactions

Jeffrey Alan Jones, Chief Medical Officer of Cullinan Therapeutics, sold 4,632 shares of common stock at $9.67 per share to cover personal income tax obligations.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, reported the sale of 2,898 common shares on December 18, 2025, to cover tax obligations from restricted stock unit vesting.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, reported sales of common stock totaling 3,143 shares across two transactions in December 2025, primarily for tax obligations and a pre-arranged trading plan.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, reported the sale of 4,000 shares of common stock at $12.3 per share under a pre-arranged plan.

Lynx1 Capital Management LP, a 10% owner and director, acquired an additional 165,667 shares of Cullinan Therapeutics common stock.

Lynx1 Capital Management LP and Weston Nichols increased their beneficial ownership in Cullinan Therapeutics, Inc. through multiple common stock purchases in mid-October 2025.

Lynx1 Capital Management LP, a 10% owner and director, significantly increased its beneficial ownership in Cullinan Therapeutics, Inc. through multiple common stock purchases.

Cullinan Therapeutics director Mittie Doyle was granted stock options to purchase 79,456 shares of common stock at an exercise price of $7.03.

Cullinan Therapeutics director Andrew R. Allen was granted 79,456 stock options with an exercise price of $7.03, vesting over three years.

Cullinan Therapeutics, Inc. Director David P. Ryan was granted 38,513 stock options with an exercise price of $8.95, vesting by June 2026 or the next annual meeting.

Cullinan Therapeutics, Inc. Director Anthony Rosenberg was granted options to purchase 38,513 shares of common stock at an exercise price of $8.95, aligning his interests with shareholder value.

Cullinan Therapeutics, Inc. Director Stephen W. Webster reported the acquisition of 38,513 stock options with an exercise price of $8.95, vesting by June 2026.

Cullinan Therapeutics, Inc. Director David D. Meek was granted an option to purchase 38,513 shares of common stock at an exercise price of $8.95 per share, as reported in a recent SEC Form 4 filing.

Cullinan Therapeutics, Inc. Director Anne-Marie Martin was granted 38,513 stock options with an exercise price of $8.95, vesting by June 2026.

Jeffrey Alan Jones, Chief Medical Officer of Cullinan Therapeutics, sold 4,895 shares of common stock on February 25, 2025, to cover personal income tax obligations.

Cullinan Therapeutics' CEO, Nadim Ahmed, sold 12,529 shares of common stock on February 25, 2025, to cover personal income tax obligations arising from the vesting of restricted stock units.

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, sold 3,756 shares of common stock to cover personal income tax obligations upon the vesting of restricted stock units.

Jacquelyn L. Sumer, Chief Legal Officer of Cullinan Therapeutics, Inc., sold 3,756 shares of common stock on February 25, 2025, to cover personal income tax obligations upon vesting of restricted stock units.

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, acquired 50,000 shares of common stock and stock options for 100,000 shares on February 19, 2025.

Corrine Savill, Chief Business Officer of Cullinan Therapeutics, reports acquisition of common stock and stock options.

Jacquelyn L. Sumer, Chief Legal Officer of Cullinan Therapeutics, reports the acquisition of stock options and restricted stock units.

Nadim Ahmed, CEO of Cullinan Therapeutics, reports acquisition of common stock and stock options.

Jeffrey Alan Jones, Chief Medical Officer of Cullinan Therapeutics, reports the acquisition of 65,000 shares of common stock and options to purchase 130,000 shares.

Cullinan Therapeutics' Chief Financial Officer, Mary Kay Fenton, reports the acquisition of 60,000 shares of common stock and 120,000 stock options.

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, sold 4,000 shares of common stock at an average price of $12.51 on January 6, 2025, under a pre-arranged 10b5-1 trading plan.

Cullinan Therapeutics CEO Nadim Ahmed sold 8,400 shares of common stock on December 24, 2024, to cover personal income tax obligations.

Jennifer Michaelson, Chief Scientific Officer of Cullinan Therapeutics, sold 4,693 shares of common stock on December 18, 2024, to cover personal income tax obligations.

Jeffrey Alan Jones, Chief Medical Officer of Cullinan Therapeutics, sold 4,632 shares of common stock on December 18, 2024, to cover personal income tax obligations upon the vesting of restricted stock units.

Jacquelyn L. Sumer, Chief Legal Officer of Cullinan Therapeutics, Inc., sold 3,482 shares of common stock on December 18, 2024, to cover personal income tax obligations.

Cullinan Therapeutics' Chief Scientific Officer, Jennifer Michaelson, sold 3,489 shares of common stock at $12.52 per share to cover personal income tax obligations.